Stevanato Group S.p.A. (STVN) Insider JR Buys 4,975 Shares
Donald Morel Jr acquired 4,975 shares of Stevanato Group on June 12, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Morel Donald JR bought 4,975 shares of Stevanato Group S.p.A. ($STVN) on June 12, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $STVN is down 0.8% after 1 week, up 15.8% after 1 month and up 10.7% to date (from the $17.08 close on Jun 12, 2026).
Key Points
- Donald Morel Jr purchased 4,975 shares of Stevanato Group on June 12, 2026, with the stock trading near $18.39 on Friday.
- Stevanato Group has a market cap of $5.02 billion and a P/E ratio of 31.7, with shares ranging from $12.89 to $28.00 over the past year.
- Insider trading activity was active with multiple transactions, and analysts have set new price targets, including TD Cowen's initiation with a $25 target.
Get $STVN trade alerts by text
We text you when insiders, Congress or big funds trade $STVN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Stevanato Group S.p.A. alert may contain errors. Disclosures
Donald Morel Jr, an insider at Stevanato Group S.p.A. (NYSE:STVN), purchased 4,975 shares of the company on June 12, 2026. The transaction did not disclose the purchase price. On Friday, Stevanato's stock traded near $18.39.
Insider Buying and Selling at Stevanato Group S.p.A.
Morel's purchase was part of a series of insider activities around the same period. On June 15, 2026, insiders including Karen Flynn, William Federici, and Madhavan Balachandran each sold 1,493 shares at an average price of $17.09. Marco Dal Lago, the Chief Financial Officer, also bought 2,356 shares on June 12, 2026, alongside Morel.
Other Institutional Activity in Stevanato Group
Several institutional investors also adjusted their holdings in Stevanato Group. Conestoga Capital Advisors, LLC increased its stake by 602,050 shares, bringing its total to 8,491,751 shares valued at approximately $116.76 million, a 7.6% increase. On the other hand, Neuberger Berman Group LLC reduced its position by 312,219 shares, holding 4,475,492 shares worth $61.54 million, a decrease of 6.5%. T. Rowe Price Investment Management, Inc. trimmed its holdings by 698,724 shares, now owning 3,224,908 shares valued at $44.34 million, marking a 17.8% decrease.
Stevanato Group S.p.A. Stock Down 4.8%
Shares of Stevanato Group traded near $18.39 on Friday. The company has a market capitalization of approximately $5.02 billion and a P/E ratio of 31.7. Its stock has seen a 52-week low of $12.89 and a high of $28.00. Stevanato Group's 50-day moving average is $17.39, while the 200-day moving average is $19.57. The company maintains a current ratio of 1.63 and a quick ratio of 1.11, with a debt-to-equity ratio of 29.43.
Recent Earnings
For its most recent quarter, Stevanato Group reported revenue of $1.20 billion, reflecting a growth of 6.6%. The net margin stood at 11.75%, and the return on equity was 9.59%. The company's earnings per share were $0.58. Stevanato Group is scheduled to announce its next earnings on May 7, 2026.
Dividend
Stevanato Group pays an annual dividend rate of $0.06, yielding 0.34% with a payout ratio of 10.59%. The company has a consistent dividend policy, providing returns to its shareholders.
Analysts Set New Price Targets
Analysts have recently updated their price targets for Stevanato Group. On June 16, 2026, TD Cowen initiated coverage with a 'buy' rating and a $25 price target. Wolfe Research assumed coverage on June 2, 2026, with a 'buy' rating and a $21 target. The consensus among analysts is a 'buy' recommendation, with an average target price of $24.45 based on 10 analyst opinions.
About Stevanato Group
Stevanato Group S.p.A. designs and produces a range of products and solutions for the healthcare and biopharma industries. Headquartered in Piombino Dese, Italy, the company operates through two segments: Biopharmaceutical and Diagnostic Solutions, and Engineering. It offers drug containment solutions, diagnostic systems, and medical devices, serving clients across the globe. Founded in 1949, Stevanato Group employs over 6,000 people and is led by CEO Franco Stevanato.
Bottom Line
Stevanato Group's recent insider buying and institutional activity reflect ongoing interest in the company. With a solid market position in the healthcare sector, investors keep an eye on its performance. Remember, insider transactions are reported after they occur, and this information is backward-looking.
Source: Morel Donald JR's Form 4 filing on $STVN (Jun 12, 2026). Find the original filing: STVN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts
